Literature DB >> 3104392

Peripheral blood mononuclear-cell interleukin-2 production, receptor generation and lymphokine-activated cytotoxicity in inflammatory bowel disease.

R H Ming, D Atluru, C W Spellman, T Imir, J S Goodwin, R G Strickland.   

Abstract

The interleukin-2 pathway is essential for the normal immune response to antigen stimulation; we have examined the possibility that this may underlie abnormal peripheral blood lymphocyte immunoregulatory function that has been observed in patients with inflammatory bowel disease. We studied 11 patients with Crohn's disease and 5 with ulcerative colitis, all with quiescent disease activity. Peripheral blood mononuclear cells were isolated from these patients and from healthy age- and sex-matched controls. Interleukin-2 production after mitogen and phorbol-myristate acetate stimulation was similar in both groups: 381 +/- 71 (mean +/- SE) U/ml by control cells and 451 +/- 70 by patient cells. Interleukin-2 receptor generation was also measured pre- and poststimulation by labeling with anti-Tac antibody. This was 10.45 +/- 1 and 69.95 +/- 3.85% for control cells and 11.41 +/- 1.38 and 60.9 +/- 4.25% for patients cells. Finally, we examined the response of these cells to interleukin-2 stimulation by generating cells with direct cytotoxicity to 51Cr-labeled Daudi-cell targets. Control cells caused 59.5 +/- 46% 51Cr release, whereas patient cells caused 50.8 +/- 5.18% release. None of the above results achieved statistical significance. We conclude that the peripheral blood interleukin-2 pathway is normal in inactive inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104392     DOI: 10.1007/bf00915426

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  13 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Immune status in Crohn's disease. VI. Immunoregulation evaluated by multiple, distinct T-suppressor cell assays of lymphocyte proliferation, and by enumeration of immunoregulatory T-lymphocyte subsets.

Authors:  I O Auer; A Röder; J Fröhlich
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

3.  Peripheral blood mononuclear cells from patients with inflammatory bowel disease exhibit normal function in the allogeneic and autologous mixed leukocyte reaction and cell-mediated lympholysis.

Authors:  R P MacDermott; M J Bragdon; R D Thurmond
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

Review 4.  Recent developments in nonspecific inflammatory bowel disease (second of two parts).

Authors:  J B Kirsner; R G Shorter
Journal:  N Engl J Med       Date:  1982-04-08       Impact factor: 91.245

5.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

6.  T-cell abnormalities in inflammatory bowel disease are mediated by interleukin 2.

Authors:  E C Ebert; S H Wright; W H Lipshutz; S P Hauptman
Journal:  Clin Immunol Immunopathol       Date:  1984-11

7.  Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  C Fiocchi; M L Hilfiker; K R Youngman; N C Doerder; J H Finke
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

8.  Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients.

Authors:  R Stevens; M Oliver; M Brogan; J Heiserodt; S Targan
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

9.  Immunoregulatory function of human intestinal mucosa lymphoid cells: evidence for enhanced suppressor cell activity in inflammatory bowel disease.

Authors:  C Fiocchi; K R Youngman; R G Farmer
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 2.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Cytokine production in patients with inflammatory bowel disease.

Authors:  M Nakamura; H Saito; J Kasanuki; Y Tamura; S Yoshida
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 4.  Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?

Authors:  M J Weldon; J D Maxwell
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

5.  Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients.

Authors:  L Manzano; M Alvarez-Mon; J A Vargas; J A Girón; L Abreu; A Fernández-Corugedo; L I Román; F Albarran; A Durántez
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

6.  Enhancement of IL-1, IL-2 production and IL-2 receptor generation in patients with acute rheumatic fever and active rheumatic heart disease; a prospective study.

Authors:  K Morris; C Mohan; P L Wahi; I S Anand; N K Ganguly
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

7.  Impaired local natural killer cell activity in human colorectal carcinomas.

Authors:  N M Aparicio-Pagés; H W Verspaget; S A Peña; C B Lamers
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  T cell cytotoxicity of autologous and allogeneic lymphocytes in a patient with Crohn's disease.

Authors:  K Okazaki; Y Yokoyama; Y Yamamoto; M Kobayashi; K Araki; T Ogata
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

9.  Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

Authors:  J Brynskov; N Tvede
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.